Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (161-170 of 223) with videos related to

Pageof 23
Sort By:
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Nature|September 10, 2020
Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancerZhong Y Yeow, Bramwell G Lambrus, Rebecca Marlow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Tiling path genomic profiling of grade 3 invasive ductal breast cancersRachael Natrajan, Maryou B Lambros, Socorro María Rodríguez-Pinilla, et al.
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2019
Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programmeMichael Davidson, Lauren I Aronson, Julie Howard-Reeves, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Cancer Discovery|October 11, 2011
Functional viability profiles of breast cancerRachel Brough, Jessica R Frankum, David Sims, et al.
Nature Cell Biology|June 2, 2026
Nucleophagy removes cytotoxic trapped PARP1Gwendoline Hoslett, Sara Tribble, Pauline Lascaux, et al.
The Journal of Pathology|December 6, 2013
The genomic landscape of oesophagogastric junctional adenocarcinomaIrene Y Chong, David Cunningham, Louise J Barber, et al.
Pageof 23

Showing results (161-170 of 223) with videos related to

Sort By:
Pageof 23
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Nature|September 10, 2020
Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancerZhong Y Yeow, Bramwell G Lambrus, Rebecca Marlow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Tiling path genomic profiling of grade 3 invasive ductal breast cancersRachael Natrajan, Maryou B Lambros, Socorro María Rodríguez-Pinilla, et al.
Cancer Research|October 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor ResistanceMarta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2019
Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programmeMichael Davidson, Lauren I Aronson, Julie Howard-Reeves, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Cancer Discovery|October 11, 2011
Functional viability profiles of breast cancerRachel Brough, Jessica R Frankum, David Sims, et al.
Nature Cell Biology|June 2, 2026
Nucleophagy removes cytotoxic trapped PARP1Gwendoline Hoslett, Sara Tribble, Pauline Lascaux, et al.
The Journal of Pathology|December 6, 2013
The genomic landscape of oesophagogastric junctional adenocarcinomaIrene Y Chong, David Cunningham, Louise J Barber, et al.
Pageof 23